Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

NCT07557914 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
32
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Haibo Shao

Collaborators